The results of this study show that novel chA21 scFv-based, HER2-specific CAR T cells not only recognised and killed HER2+ breast and ovarian cancer cells ex vivo but also induced regression of experimental breast cancer in vivo. This evidence concerns the gene ERBB2 and breast carcinoma.